Rubicon Research Limited.
Healthcare · Pharmaceuticals
Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. The company develops products in the areas of analgesics/pain management, cardiovascular system, central nervous system, hypokalemia, skeletal muscle relaxants, nicotine replacement therapy, gastrointestinal, metabolic, and immunosuppressant. Its primary proprietary technologies for drug delivery comprising RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption, as well as RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies. The company was incorporated in 1999 and is headquartered in Mumbai, India.
- Market cap
- ₹27,675 cr
- P/E (TTM)
- 95.2
- P/B (latest)
- 21.5
- ROE (TTM)
- 19.1%
- ROCE (TTM)
- 24.5%
- Sales CAGR 3y
- 64.6%
- PAT CAGR 3y
- 0%
- Debt / equity
- 0.2x
- Promoter
- 59.8%
- Dividend yield
- 0.09%
- Size
- Micro
- Codes
- RUBICON · 544578
₹1,592.8 · 28 Sept 2026
52-week ₹577.25 – ₹1,860.6 · ADTV ₹54.4 cr · price-only.
Sales and net profit by fiscal year, ₹ crore
Not in the Buoyant book: no house thesis or target is carried. Exchange masters, Tijori and the reference price feed as stated on each tab. All listed companies · NSE EQ